Table 1 –

Parameter Overview: Overview of key model parameters along with data sources used for model calibration and testing. Units in brackets, distributions in curly brackets, and 95% confidence intervals in parentheses for parameters fitted in this work.

Key Model Parameters – Estimated From Literature & Previous Studies
Parameter	Description	Value	Source
Ncells(0)	initial number of local clonogens	[9.1*106 – 6.7*1011] [cells]	Geng et al.(18)
K	gompertzian carrying capacity	8.2*1012 [cells]	Geng et al.(18)
Vp(0) = Npersistent(0)/Ncells(0) Vr(0) = Npersistent(0)/Ncells(0)	initial fraction of TKI persistent & TKI resistant clonogens	[0.05 – 0.5] [-] [10−4 – 10−1] [-]	Grassberger et al.(12)
μ	resistant mutation probability	10−7 [-]	Grassberger et al.(12)
βTKI	TKI cell kill parameter	trunc-norm {μ=2, σ=7} [ml/μg]; (>1)	Grassberger et al.(12)
βc	chemotherapy cell kill parameter	trunc-norm {μ=.028, σ=6.8*10−4} [m2/mg]; (>0)	Geng et al.(18)
t1/2	chemotherapy plasma half life	24 [hr]	Geng et al.(18)
κ	TKI plasma decay factor	0.0465 [hr−1]	Grassberger et al.(12), Foo et al.(30)
rdeath	comorbidity death rate for regional lung cancer	0.55 [%/mo]	SEER(20, 21)
Key Model Parameters – Derived In Current Study
Parameter	Description	Value	Source
fmet	initial number of metastatic clonogens as a fraction of Ncells(0)	2*10−6 (CI: 7.5*10−7 – 4*10−6) [-]	this work
ρ	NSCLC growth rate	trunc-norm {μ=7*10−5, σ=.0055 (CI: .005–.007)} [day−1]; (>0)	this work
α	WT NSCLC radiosensitivity	trunc-norm {μ=.10 (CI: .04–.18), σ=.17 (CI: .11–.2)} [Gy−1]; (>0)	this work
αEGFR	EGFR-mutant NSCLC radiosensitivity	trunc-norm {μ=.16 (CI: .10–.26), σ=.32 (CI: .20–.44)} [Gy−1]; (>0)	this work
Clinical Data used for Calibrating & Testing Model In Current Study
Dataset	Description	Endpoint	Source
Calibration (N=118, USA)	institutional LF & DF rates in EGFR-mutant/WT LA-NSCLC	FFLF & FFDF [mo]	Mak et al.(24)
Calibration (N=95, Japan)	institutional LF & DF rates in EGFR-mutant /WT LA-NSCLC	FFLF & FFDF [mo]	Lim et al.(23)
Calibration (N=185, S. Korea)	institutional LF & DF rates in EGFR-mutant /WT LA-NSCLC	FFLF & FFDF [mo]	Yagishita et al.(19)
Testing (N=86, France, Italy, Spain)	phase III clinical trial of TKIs in metastatic NSCLC (NCT00446225)	PFS [mo]	EURTAC Trial, Rosell et al.(1)
Testing (N=598, Worldwide)	phase III clinical trial of concurrent chemoradiation in locally advanced NSCLC (NCT00686959)	PFS [mo]	PROCLAIM Trial, Senan et al.(35)
Testing (N=6 Clinical Trials)	meta-analysis of 6 clinical trials of sequential versus concurrent chemoradiotherapy in LA-NSCLC	FFLF & FFDF [mo]	Auperin et al.(36)